Oncolytic virotherapy

Wadhwa, 2002, Cancer Gene Therapy: Scientific Basis., Annu Rev Med, 53, 427, 10.1146/annurev.med.53.082901.104039

Everts, 2005, Replication-selective oncolytic viruses in the treatment of cancer, Cancer Gene Ther, 12, 141, 10.1038/sj.cgt.7700771

Stanford, 2007, Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells, J Virol, 81, 1251, 10.1128/JVI.01408-06

Lun, 2005, Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas, Cancer Res, 65, 9982, 10.1158/0008-5472.CAN-05-1201

Donofrio, 2005, Potential secondary pathogenic role for bovine herpesvirus 4, J Clin Microbiol, 43, 3421, 10.1128/JCM.43.7.3421-3426.2005

Gillet, 2005, Bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines in vitro and in vivo, Cancer Res, 65, 9463, 10.1158/0008-5472.CAN-05-1076

Norman, 2004, Reovirus oncolysis: the Ras/Ral GEF/p3 8 pathway dictates host cell permissiveness to reovirus infection, Proc Natl Acad Sci, 101, 11099, 10.1073/pnas.0404310101

Marcato, 2005, Connecting reovirus oncolysis and Ras signaling, Cell Cicle, 4, 556, 10.4161/cc.4.4.1600

Phuangsab, 2001, Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration, Cancer Lett, 172, 27, 10.1016/S0304-3835(01)00617-6

Mullen, 2002, Viral oncolysis, Oncologist, 7, 106, 10.1634/theoncologist.7-2-106

Elankumaran, 2006, Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase- dependent pathways of cell death, J Virol, 80, 7522, 10.1128/JVI.00241-06

Shafren, 1997, Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry, J Virol, 71, 4736, 10.1128/JVI.71.6.4736-4743.1997

Shafren, 2004, Systemic therapy of malignant human melanoma tumors by a common cold- producing enterovirus, Coxsackievirus A21, Clin Cancer Res, 10, 53, 10.1158/1078-0432.CCR-0690-3

Letchworth, 1999, Vesicular stomatitis, Vet J, 157, 239, 10.1053/tvjl.1998.0303

Barber, 2004, Vesicular stomatitis virus as an oncolytic vector, Viral Immunol, 17, 516, 10.1089/vim.2004.17.516

Balachandran, 2001, Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis, J Virol, 75, 3474, 10.1128/JVI.75.7.3474-3479.2001

Connor, 2004, Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hy- poxic tumor cells in vitro and in vivo, J Virol, 78, 8960, 10.1128/JVI.78.17.8960-8970.2004

Connor, 2005, Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation, Biol Chem, 280, 13512, 10.1074/jbc.M501156200

Russell, 2002, RNA viruses as virotherapy agents, Cancer Gene Ther, 9, 961, 10.1038/sj.cgt.7700535

Di Piazza, 2007, Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells, J Virol, 81, 4186, 10.1128/JVI.02601-06

Herrero y Calle, 2004, Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing, Int J Cancer, 109, 76, 10.1002/ijc.11626

Geletneky, 2005, Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review, J Vet Med, 52, 327, 10.1111/j.1439-0450.2005.00877.x

Smith, 1956, Studies on the use of viruses in the treatment of carcinoma of the cervix, Cancer, 9, 1211, 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7

Ludlow, 1995, Viral oncoprotein binding to pRb, p107, p130, and p300, Virus Res, 35, 113, 10.1016/0168-1702(94)00094-S

Green, 2002, Adenoviral vectors: Systemic delivery and tumor targeting, Cancer Gene Ther, 9, 1036, 10.1038/sj.cgt.7700541

Dahiya, 2000, Role of the LXCXE binding site in Rb function, Moi Ceii Bioi, 20, 6799

Alevizopoulos, 2000, Conserved region 2 of adenovirus E1A has function distinct from pRb binding required to prevent cell cycle arrest by p16INK4 or p27Kip1, Oncogene, 19, 2067, 10.1038/sj.onc.1203534

Wienzek, 2000, E1B 55-kilodaltons oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53, J Viroi, 74, 193, 10.1128/JVI.74.1.193-202.2000

Zhao, 2003, Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis, J Viroi, 77, 13171, 10.1128/JVI.77.24.13171-13181.2003

Hickman, 2002, The role of p53 and pRb in apoptosis and cancer, Curr Opin Genet Dev, 12, 60, 10.1016/S0959-437X(01)00265-9

Liu, 2005, Viruses with deletions in antiapoptotic genes as potential oncolytic agents, Oncogene, 24, 6069, 10.1038/sj.onc.1208734

Berk, 2005, Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus, Oncogene, 24, 7673, 10.1038/sj.onc.1209040

Robson, 2003, Transcriptional targeting in cancer gene therapy, J Biomed Biotechnoi, 110, 10.1155/S1110724303209074

Sadeghi, 2005, Transcriptionally targeted adenovirus vectors, Curr Gene Ther, 5, 411, 10.2174/1566523054546189

Kanerva, 2004, Modified adenovirus for cancer gene therapy, Int J Cancer, 110, 475, 10.1002/ijc.20129

Post, 2003, Replicative oncolytic adenoviruses in multimodal cancer regimens, Hum Gene Ther, 14, 933, 10.1089/104303403766682205

Bischoff, 1996, An adenovirus mutant that replicates selectively in p53-defi- cient human tumor cells, Science, 274, 373, 10.1126/science.274.5286.373

Kirn, 2001, Oncolytic virotherapy for cancer with the adenovirus dl1520 (0nyx-015): results of phase I and II trials, Expert Opin Bioi Ther, 1, 525, 10.1517/14712598.1.3.525

Fueyo, 2000, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect, in vivo. Oncogene, 19, 2, 10.1038/sj.onc.1203251

Gomez-Manzano, 2004, A novel E1A-E1B mutant adenovirus induces glioma regression, in vivo. Oncogene, 23, 1821, 10.1038/sj.onc.1207321

Heise, 2000, 2000. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy, Nat Med, 6, 1134, 10.1038/80474

Harrington, 2000, Transcriptional control: an essential component of cancer gene therapy strategies?, Adv Drug Deiiv Rev, 44, 167, 10.1016/S0169-409X(00)00093-4

Rodriguez, 1997, Prostate attenuated replication competent ad- enovirus (ARCA) CN706: a selective cytotoxic for prostate- specific antigen-positive prostate cancer cells, Cancer Res, 57, 2559

Lee, 2004, Combination therapy with conditionally replicating adenovirus and replication defective adenovirus, Cancer Res, 64, 6660, 10.1158/0008-5472.CAN-04-1200

Li, 2003, Carcinoembrionic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy, Mol Cancer Ther, 2, 1003

Hallenbeck, 1999, A novel tumor-specific replication- restricted adenoviral vector for gene therapy of hepatocellular carcinoma, Hum Gene Ther, 10, 1721, 10.1089/10430349950017725

Delgado-Enciso, 2007, A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms, J Gene Med, 9, 852, 10.1002/jgm.1071

Excoffon, 2005, The role of the extracellular domain in the biology of the coxsackievirus and adenovirus receptor, Am J Respir Cell Mol Biol, 32, 498, 10.1165/rcmb.2005-0031OC

McConnel, 2004, Biology of adenovirus and its use as a vector for gene therapy, Hum Gene Ther, 15, 1022, 10.1089/hum.2004.15.1022

Volk, 2003, Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism, Cancer Biol Ther, 2, 511, 10.4161/cbt.2.5.440

Martin, 2005, The Coxsackie-adenovirus receptor has elevated expression in human breast cancer, Clin Exp Med, 5, 122, 10.1007/s10238-005-0076-1

Campbell, 2003, An aden- oviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression, Cancer Gene Ther, 10, 559, 10.1038/sj.cgt.7700599

Dehari, 2003, Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer, Cancer Gene Ther, 10, 75, 10.1038/sj.cgt.7700529

Liu, 2004, Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma, Hum Gene Ther, 15, 637, 10.1089/1043034041361181

Taki, 2005, Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent 0BP-405 (‘Telomelysin-RGD’), Oncogene, 24, 3130, 10.1038/sj.onc.1208460

Denby, 2004, Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo, Hum Gene Ther, 15, 1054, 10.1089/hum.2004.15.1054

Krasnykh, 1996, Generation of recombinant adenovirus vectors modified fibers for altering viral tropism, J Virol, 70, 6839, 10.1128/JVI.70.10.6839-6846.1996

Parker, 2006, Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes, Blood, 108, 2554, 10.1182/blood-2006-04-008532

Parker, 2007, Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D, J Virol, 181, 3627, 10.1128/JVI.02786-06

Douglas, 1996, Targeted gene delivery by tropism-modified adenoviral vectors, Nat Biotechnol, 14, 1574, 10.1038/nbt1196-1574

Ranki, 2007, A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer, Gene Ther, 14, 58, 10.1038/sj.gt.3302830

Zhang, 2004, Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene, Cancer Res, 64, 5390, 10.1158/0008-5472.CAN-04-1229

Ren, 2006, A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepa- tocellular carcinoma, Cancer Gene Ther, 13, 159, 10.1038/sj.cgt.7700868

Guo, 2006, Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syn- geneic murine breast cancer models, Cancer Gene Ther, 13, 82, 10.1038/sj.cgt.7700863

Zhang, 2003, An armed oncolytic adenovirus system, ZD55- gene, demonstrating potent antitumoral efficacy, Cell Res, 113, 481, 10.1038/sj.cr.7290191

Oosterhoff, 2005, Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus Ad***entity*** 24, Gene Ther, 12, 1011, 10.1038/sj.gt.3302492

Dilley, 2005, Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity, Cancer Gene Ther, 12, 715, 10.1038/sj.cgt.7700835

Méndez-Sánchez, 2007, Hepatocellular carcinoma in Hispanics, Ann Hepatol, 6, 279, 10.1016/S1665-2681(19)31913-1

Shinozaki, 2005, Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV, Hepatology, 41, 196, 10.1002/hep.20536

Blechacz, 2006, Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma, Hepatology, 44, 1465, 10.1002/hep.21437

Su, 2006, Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma, World J Gastroenterol, 12, 7613, 10.3748/wjg.v12.i47.7613

Zhang, 2006, Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus, Clin Cancer Res, 12, 6523, 10.1158/1078-0432.CCR-06-1491

Wirth, 2005, Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1, Cancer Res, 65, 7393, 10.1158/0008-5472.CAN-04-3664

Prince, 1993, Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus), J Virol, 67, 101, 10.1128/JVI.67.1.101-111.1993

Rojas-Martinez, 1998, Aguilar-Cordova E. Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat, Cancer Gene Ther, 5, 365

Toth, 2005, Cotton rat tumor model for the evaluation of oncolytic adenoviruses, Hum Gene Ther, 16, 139, 10.1089/hum.2005.16.139

Eichelberger, 2007, The cotton rat as a model to study influenza pathogenesis and immunity, Viral Immunol, 20, 243, 10.1089/vim.2007.0017

Ottolini, 2005, The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis, J Gen Virol, 86, 2823, 10.1099/vir.0.81145-0

Zhao, 2006, In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants, J Virol, 80, 11651, 10.1128/JVI.01387-06

Yim, 2005, The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies, J Virol, 79, 14632, 10.1128/JVI.79.23.14632-14639.2005

Williams, 2005, The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity, J Virol, 79, 10944, 10.1128/JVI.79.17.10944-10951.2005

Rytik, 2004, Small animal model of HIV-1 infection., J Clin Virol, Suppl 1, S83, 10.1016/j.jcv.2004.09.010

Mahler, 2005, Experimental Helicobacter pylori infection induces antral-predominant, chronic active gastritis in hispid cotton rats (Sigmodon hispidus), Helicobacter, 10, 332, 10.1111/j.1523-5378.2005.00320.x

Steel, 2007, Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus, Virology, 369, 131, 10.1016/j.virol.2007.07.022

Clyde, 1980, Experimental models for study of common respiratory viruses, Environ Health Perspect, 35, 107, 10.1289/ehp.8035107

Kunstyr, 1984, Adenovirus pneumonia in guineapigs: an experimental reproduction of the disease, Lab Anim, 18, 55, 10.1258/002367784780864866

Jogler, 2006, Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species, J Virol, 80, 3549, 10.1128/JVI.80.7.3549-3558.2006

Thomas, 2006, Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors, Cancer Res, 66, 1270, 10.1158/0008-5472.CAN-05-3497

Hara, 2007, Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster, Cancer Sci, 98, 455, 10.1111/j.1349-7006.2007.00408.x

Pecora, 2002, Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers, J Clin Oncol, 20, 2220, 10.1200/JCO.2002.08.042

Khuri, 2000, A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluo- rouracil in patients with recurrent head and neck cancer, Nat Med, 6, 879, 10.1038/78638

Nemunaitis, 2001, Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer, J Clin Oncol, 19, 289, 10.1200/JCO.2001.19.2.289

Lu, 2004, Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial, World J Gastroenterol, 10, 3634, 10.3748/wjg.v10.i24.3634

Aghi, 2005, Oncolytic viral therapies - the clinical experience, Oncogene, 24, 7802, 10.1038/sj.onc.1209037